We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Excimer Lamp Versus Excimer Laser in Vitiligo Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00696358
Recruitment Status : Completed
First Posted : June 12, 2008
Last Update Posted : October 31, 2008
Information provided by:

Study Description
Brief Summary:

308 nm excimer lamp and 308 nm excimer laser have both provide interesting results in treating vitiligo. They have the same wavelength but the type of emission of the photons is different. To date there is no direct comparative data concerning these two devices in this indication.

The aim of the study is to make an intra-individual prospective comparison between these two phototherapies.

Condition or disease Intervention/treatment Phase
Vitiligo Radiation: 308nm excimer lamp Radiation: 308nm excimer laser Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Official Title: Comparative Study of 308nm Excimer Lamp and 308nm Excimer Laser in the Treatment of Vitiligo

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitiligo
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: A
308 nm excimer lamp
Radiation: 308nm excimer lamp
50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks
Active Comparator: B
308 nm excimer laser
Radiation: 308nm excimer laser
50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks (same doses will be used between the 2 arms)

Outcome Measures

Primary Outcome Measures :
  1. Repigmentation rate in the treated areas [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Tolerance and safety of the treatments [ Time Frame: 12 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patient above 18
  • vitiligo for more than 3 months
  • at least 2 vitiligo symmetric patches more than 10cm²
  • to read and understand the inform consent
  • to have a social security number
  • non pregnant for women

Exclusion Criteria:

  • pregnant women
  • keloids
  • history of radiotherapy or skin cancer in the treated areas
  • treatment for vitiligo in the past 4 weeks
  • phototherapy in the past 12 weeks; history of photodermatosis
  • treatment inducing photosensibilization
  • immunosuppression
  • patient who participated in a study in the past 3 months
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00696358

Department of Dermatology, University Hospital of Nice
Nice, France, 06200
Sponsors and Collaborators
Centre Hospitalier Universitaire de Nice
More Information

ClinicalTrials.gov Identifier: NCT00696358     History of Changes
Other Study ID Numbers: NICE-VIT1
First Posted: June 12, 2008    Key Record Dates
Last Update Posted: October 31, 2008
Last Verified: October 2008

Keywords provided by Centre Hospitalier Universitaire de Nice:

Additional relevant MeSH terms:
Pigmentation Disorders
Skin Diseases